🚀 VC round data is live in beta, check it out!
AIM Vaccine Valuation Multiples
Discover revenue and EBITDA valuation multiples for AIM Vaccine and similar public comparables like Armata Pharmaceuticals, Recbio, Shanghai Hile Bio-Tech, Lineage Cell Therapeutics and more.
AIM Vaccine Overview
About AIM Vaccine
AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain, ranging from research and development to manufacturing and commercialization. The Vaccine products include Recombinant HBV Vaccines, Freeze-dried Human Rabies Vaccine, Inactivated HAV Vaccines, Group A, C, Y, and W135 MPSV, Bivalent Inactivated HFRS Vaccine, and Mumps Vaccine. It generates the majority of its revenues in the PRC.
Founded
2011
HQ
Employees
1.5K
Website
Sectors
Financials (LTM)
EV
$621M
AIM Vaccine Financials
AIM Vaccine reported last 12-month revenue of $169M.
In the same LTM period, AIM Vaccine generated had net loss of ($98M).
Revenue (LTM)
AIM Vaccine P&L
In the most recent fiscal year, AIM Vaccine reported revenue of $188M and EBITDA of ($8M).
AIM Vaccine expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $169M | XXX | $188M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $140M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 74% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (5%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (16%) | XXX | XXX | XXX |
| Net Profit | ($98M) | XXX | ($41M) | XXX | XXX | XXX |
| Net Margin | (58%) | XXX | (22%) | XXX | XXX | XXX |
| Net Debt | — | — | $194M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AIM Vaccine Stock Performance
AIM Vaccine has current market cap of $419M, and enterprise value of $621M.
Market Cap Evolution
AIM Vaccine's stock price is $0.34.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $621M | $419M | -7.2% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAIM Vaccine Valuation Multiples
AIM Vaccine trades at 3.7x EV/Revenue multiple, and (73.1x) EV/EBITDA.
EV / Revenue (LTM)
AIM Vaccine Financial Valuation Multiples
As of April 18, 2026, AIM Vaccine has market cap of $419M and EV of $621M.
Equity research analysts estimate AIM Vaccine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AIM Vaccine has a P/E ratio of (4.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $419M | XXX | $419M | XXX | XXX | XXX |
| EV (current) | $621M | XXX | $621M | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (73.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (20.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.4x | XXX | XXX | XXX |
| P/E | (4.3x) | XXX | (10.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (30.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified AIM Vaccine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
AIM Vaccine Margins & Growth Rates
AIM Vaccine's revenue in the last fiscal year declined by (10%).
AIM Vaccine's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
AIM Vaccine Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (10%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (5%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (97%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 42% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 22% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 28% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 91% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
AIM Vaccine Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| AIM Vaccine | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Recbio | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai Hile Bio-Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Rocket Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AIM Vaccine M&A Activity
AIM Vaccine acquired XXX companies to date.
Last acquisition by AIM Vaccine was on XXXXXXXX, XXXXX. AIM Vaccine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by AIM Vaccine
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAIM Vaccine Investment Activity
AIM Vaccine invested in XXX companies to date.
AIM Vaccine made its latest investment on XXXXXXXX, XXXXX. AIM Vaccine invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by AIM Vaccine
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout AIM Vaccine
| When was AIM Vaccine founded? | AIM Vaccine was founded in 2011. |
| Where is AIM Vaccine headquartered? | AIM Vaccine is headquartered in China. |
| How many employees does AIM Vaccine have? | As of today, AIM Vaccine has over 1K employees. |
| Who is the CEO of AIM Vaccine? | AIM Vaccine's CEO is Yan Zhou. |
| Is AIM Vaccine publicly listed? | Yes, AIM Vaccine is a public company listed on HKEX. |
| What is the stock symbol of AIM Vaccine? | AIM Vaccine trades under 06660 ticker. |
| When did AIM Vaccine go public? | AIM Vaccine went public in 2022. |
| Who are competitors of AIM Vaccine? | AIM Vaccine main competitors are Armata Pharmaceuticals, Recbio, Shanghai Hile Bio-Tech, Lineage Cell Therapeutics. |
| What is the current market cap of AIM Vaccine? | AIM Vaccine's current market cap is $419M. |
| What is the current revenue of AIM Vaccine? | AIM Vaccine's last 12 months revenue is $169M. |
| What is the current revenue growth of AIM Vaccine? | AIM Vaccine revenue growth (vs. last FY) is (10%). |
| What is the current EV/Revenue multiple of AIM Vaccine? | Current revenue multiple of AIM Vaccine is 3.7x. |
| Is AIM Vaccine profitable? | No, AIM Vaccine is not profitable. |
| What is the current net income of AIM Vaccine? | AIM Vaccine's last 12 months net income is ($98M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.